Richard Gregory
Director/Board Member at CANBRIDGE PHARMACEUTICALS INC.
Net worth: 10 224 $ as of 30/03/2024
Profile
Richard James Gregory is an Independent Non-Executive Director at CANbridge Pharmaceuticals Inc. He previously held positions as an Independent Director at ProMIS Neurosciences, Inc. from 2016 to 2023, Chief Scientific Officer & Director at Canbridge Pharmaceuticals, Inc. (United States), Independent Director at Homology Medicines, Inc., Chief Scientific Officer & Executive VP-Research at ImmunoGen, Inc. from 2015 to 2019, and Head-Research & Development at Genzyme Corp.
from 2011 to 2014.
Dr. Gregory obtained a doctorate degree from the University of Massachusetts in 1986 and an undergraduate degree from Virginia Polytechnic Institute & State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.01% | 16/04/2023 | 600 ( 0.01% ) | 10 224 $ | 30/03/2024 |
| 04/05/2023 | 0 ( -.--% ) | - $ | 30/03/2024 |
Richard Gregory active positions
| Companies | Position | Start |
|---|---|---|
| CANBRIDGE PHARMACEUTICALS INC. | Director/Board Member | 20/04/2020 |
Former positions of Richard Gregory
| Companies | Position | End |
|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Director/Board Member | 26/04/2023 |
| IMMUNOGEN, INC. | Chief Tech/Sci/R&D Officer | 29/08/2019 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 31/12/2013 |
Canbridge Pharmaceuticals, Inc. (United States)
 Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Chief Tech/Sci/R&D Officer | - |
| Q32 BIO INC. | Director/Board Member | - |
Training of Richard Gregory
| University of Massachusetts | Doctorate Degree |
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
| Private companies | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Health Technology |
- Stock Market
- Insiders
- Richard Gregory
